Clinical trials: Infliximab
Plaque Psoriasis, Psoriatic Arthritis
A Clinical Study of Increased Dose of TA-650 in Patients With Psoriasis
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of TA-650 at increased dose of 10 mg/kg every 8 weeks in patients with psoriasis in whom effect of the treatment was confirmed after the treatment…
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Pustular Psoriasis (Excluding a Localized), Psoriatic Erythroderma
- Trial name
- NCT01680159
- Testing
- TA-650
- Where
- 7 sites in Japan
- Volunteers
- 51 people
- Sponsor
- Tanabe Pharma Corporation
Rheumatoid Diseases, Rheumatoid Arthritis
Post-Marketing Use Of CT-P13 (Infliximab) For Standard Of Care Treatment Of Rheumatoid Diseases Who Are Naïve To Biologics Or Switched From Remicade
To assess persistence of CT-P13 in patients with Rheumatoid Diseases (Rheumatoid arthritis [RA], ankylosing spondylitis [AS], and psoriatic arthritis [PsA]) who are naïve to biologics or are switching from stable Remicade to…
- Conditions
- Rheumatoid Diseases, Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis
- Trial name
- PERSIST (NCT02605642)
- Testing
- CT-P13
- Where
- 38 sites in Bulgaria, Canada and 5 more
- Volunteers
- 351 people
- Sponsor
- Pfizer
Psoriasis
A Study to Evaluate Remicade (Infliximab) in Moderate-to-Severe Chronic Plaque Psoriasis in the Middle Eastern Population (Study P04528)
Middle Eastern subjects with moderate-to-severe chronic plaque psoriasis will be administered infusions of infliximab (Remicade) at 5 mg/kg of body weight at Weeks 0, 2, 6, 14, and 22.
- Trial name
- NCT00687362
- Testing
- Infliximab
- Volunteers
- 22 people
- Sponsor
- Merck Sharp & Dohme LLC
Graft Versus Host Disease, Steroid Refractory GVHD
Infliximab and Basiliximab for Treatment of Steroid Refractory Acute Graft Versus Host Disease
Acute Graft Versus Host Disease (GVHD) is a serious medical condition that is a common development after Bone Marrow Transplant (BMT).
- Conditions
- Graft Versus Host Disease, Steroid Refractory GVHD, Acute GVH Disease
- Trial name
- NCT01485055
- Testing
- Infliximab and Basiliximab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Nationwide Children's Hospital
Rheumatoid Arthritis
A Phase 3 Study of NI-071 in Participants With Rheumatoid Arthritis (RADIANCE)
The purpose of this study was to demonstrate similarity of NI-071 (proposed biosimilar to infliximab) to US REMICADE® (reference product) in terms of safety and efficacy in participants with rheumatoid arthritis (RA) not…
- Trial name
- NCT02990806
- Testing
- NI-071, Remicade
- Where
- 134 sites in United States, Czechia and 6 more
- Volunteers
- 683 people
- Sponsor
- Nichi-Iko Pharmaceutical Co., Ltd.
Berylliosis, Beryllium Disease
Beryllium Infliximab Study: Clinical Interventional Trial
The goal of this research study is to test the clinical effectiveness of a drug called infliximab (Remicade) in chronic beryllium disease (CBD).
- Trial name
- BISCIT (NCT00111917)
- Testing
- Infliximab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Maier, Lisa, M.D.
Crohn's Disease
Evaluation of Capsule Endoscopy in Patients With Suspected Crohn's Disease
The aim of this study is to validate the ability of Capsule Endoscopy (CE) to accurately diagnose small bowel (SB) Crohns disease in patients with symptoms of abdominal pain and diarrhea.
- Trial name
- MA-51 (NCT00487396)
- Testing
- Capsule Endoscopy
- Where
- 11 sites in United States, Canada and 2 more
- Volunteers
- 98 people
- Sponsor
- Medtronic - MITG
Crohn's Disease
A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence
REMICADE (infliximab) is a drug used to treat active Crohn's disease and is being tested in an experiment to see if it may be useful in preventing relapse of Crohn's disease after surgical resection.
- Trial name
- NCT01190839
- Testing
- Infliximab
- Where
- 142 sites in United States, Australia and 12 more
- Volunteers
- 297 people
- Sponsor
- Janssen Biotech, Inc.
Spondylitis, Ankylosing, SpA
Enthesitis With Ultra Sonography Doppler in Spondyloarthropathies Treated With Infliximab (Study P04440)
Subjects will be given 3 infusions of infliximab according to the label at week 0, 2, and 6. Subjects will be followed for a maximum of 18 weeks or until relapse.
- Trial name
- EUSpA (NCT00686894)
- Testing
- PDUS, Infliximab
- Volunteers
- 7 people
- Sponsor
- Merck Sharp & Dohme LLC
Arthritis, Psoriatic
Investigation of 9 Consecutive Infusions of Remicade for Psoriatic Arthritis in Austria (Study P04264)
This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time interval of Remicade (Infliximab) infusions in psoriatic arthritis (PsA).
- Trial name
- NCT00725296
- Testing
- Remicade (Infliximab)
- Volunteers
- 178 people
- Sponsor
- Merck Sharp & Dohme LLC
Crohn's Disease
Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab
To assess the clinical efficacy of subcutaneous (sc) certolizumab pegol administration over 26 weeks in patients suffering from Crohn's Disease (CD) and previously treated with infliximab
- Trial name
- NCT00308581
- Testing
- Certolizumab pegol
- Where
- 107 sites in United States, Austria and 12 more
- Volunteers
- 539 people
- Sponsor
- UCB Pharma
Rheumatoid Arthritis
Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
The purpose of this clinical research study is to learn if Abatacept or Infliximab in combination with Methotrexate demonstrate a greater reduction in disease activity over placebo.
- Trial name
- NCT00095147
- Testing
- Abatacept (ABA) + Methotrexate (MTX), double-blind (DB), Infliximab (INF) + MTX, DB, PLA + MTX switched to ABA+ MTX, DB
- Where
- 76 sites in United States, Argentina and 15 more
- Volunteers
- 431 people
- Sponsor
- Bristol-Myers Squibb
Arthritis, Rheumatoid
An Efficacy and Safety Study of Infliximab in Participants With Rheumatoid Arthritis
The purpose of this study is to compare the effectiveness of iInfliximab plus methotrexate (MTX) in treatment of Rheumatoid rheumatoid Arthritis arthritis (RA) (it is an autoimmune disease that causes pain, swelling, stiffness…
- Trial name
- NCT00896168
- Testing
- Infliximab, Methotrexate
- Volunteers
- 234 people
- Sponsor
- Xian-Janssen Pharmaceutical Ltd.
Arthritis, Rheumatoid, Spondylitis, Ankylosing
Post Marketing Surveillance Study of Remicade in Patients With Chronic Inflammatory Diseases (P04840)
This study will be performed to evaluate and document the safety and efficacy of infliximab (Remicade®) in the treatment of chronic inflammatory diseases in big cohorts in the daily routine practice of rheumatologists…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Psoriasis
- Trial name
- REMission (NCT00727298)
- Testing
- Infliximab
- Volunteers
- 4,485 people
- Sponsor
- Merck Sharp & Dohme LLC
Chronic Uveitis
Multi Center Prospective Registry of Infliximab Use for Childhood Uveitis
The primary objective of this study is to examine the efficacy of infliximab for the treatment of persistent uveitis in children.
- Trial name
- NCT00589628
- Testing
- infliximab
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Egla C. Rabinovich
Crohn's Disease
Understanding the Relationship Between Infliximab Levels to Clinical Response of Remicade in Crohn's Disease
The purpose of this study is to improve the investigators understanding of the relationship between Crohn's disease and blood levels of the drug infliximab (Remicade).
- Trial name
- NCT01438151
- Testing
- Remicade
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Shradha Agarwal
Kawasaki Disease
Infliximab (Remicade) for Patients With Acute Kawasaki Disease
This study evaluates the safety of infliximab in infants and children with acute Kawasaki Disease.
- Trial name
- NCT00271570
- Testing
- Infliximab (Remicade), Intravenous immunoglobulin (IVIG)
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of California, San Diego
Spondylitis, Ankylosing, Arthritis, Rheumatoid
An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis Participants
The purpose of this observational study is to evaluate the safety and effectiveness of infliximab injection under actual conditions of use in participants, and to learn more about its adverse events.
- Conditions
- Spondylitis, Ankylosing, Arthritis, Rheumatoid, Psoriasis, Arthritis, Psoriatic
- Trial name
- NCT00760669
- Testing
- Infliximab; observational study, Methotrexate; observational study
- Volunteers
- 1,061 people
- Sponsor
- Janssen Korea, Ltd., Korea
Rheumatoid Arthritis
RHYTHM (Formerly Escape II Myocardium)
For aim 1, the proposed studies will be performed in 150 patients with RA and 25 subjects without RA (healthy volunteers) who will function as controls.
- Trial name
- RHYTHM (NCT01548768)
- Testing
- TNF inhibitors, DMARDs
- Where
- United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Columbia University
Crohn's Disease
Treatment With Infliximab in a Medical Setting (Study P05587)
This is an open-label, interventional study where a subset of participants will be randomized to one of two treatment-optimization strategies.
- Trial name
- OPTIMIST (NCT00752622)
- Testing
- Infliximab 5 mg/kg, Infliximab 5 mg/kg every 6 weeks, Infliximab 7 mg/kg every 8 weeks
- Volunteers
- 100 people
- Sponsor
- Merck Sharp & Dohme LLC